NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,002.57 mln
Float88.24 mln
Earnings Date11/09/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.5
Highly suspicious
1-Year Forecast
52.15
Transformational upside
Relative Strength
91
/ 100
Top performer
Debt / Equity
0.23
Very low leverage
ROE
-7.79
Negative
Business Description
Beam Therapeutics is a Cambridge, Massachusetts-based biotech company founded in 2017 that develops targeted gene-editing treatments for patients with serious inherited conditions. The company is advancing a pipeline of therapies for blood disorders and genetic diseases, including treatments for sickle cell disease, alpha-1 antitrypsin deficiency, and several rare liver conditions. Beam also works with partners such as Pfizer, Verve Therapeutics, and Orbital Therapeutics to expand its gene-editing research across the liver, muscle, and nervous system.
